ZFP91 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bufalin (SCHEMBL165666)	1.00	1/20
Bufalin (SCHEMBL8257006)	1.00	1/20
Bufalin (SCHEMBL1346952)	0.93	1/20
Bufalin (SCHEMBL11205069)	0.85	1/20
SCHEMBL1483968	0.76	1/20
Gamabufotalin (SCHEMBL866038)	0.75	1/20
Gamabufotalin (SCHEMBL866039)	0.75	1/20
Gamabufotalin (SCHEMBL1484413)	0.75	1/20
SCHEMBL1483302	0.75	1/20
SCHEMBL1483359	0.75	1/20
SCHEMBL1483677	0.75	1/20
SCHEMBL5082699	0.75	1/20
SCHEMBL1484109	0.74	1/20
SCHEMBL1483701	0.74	1/20
SCHEMBL3364225	0.74	1/20
SCHEMBL3364229	0.74	1/20
SCHEMBL7286202	0.74	1/20
SCHEMBL7286487	0.74	1/20
SCHEMBL12038720	0.74	1/20
SCHEMBL12057551	0.74	1/20

Clinical trials — most relevant to ZFP91 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Lipodystrophy in HIV-Infected Pateints	PHASE4	COMPLETED
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children	PHASE1/PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Decitabine in Treating Patients With Myelofibrosis	PHASE2	ACTIVE_NOT_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Natural History Study of GATA2 Deficiency and Related Disorders	nan	RECRUITING
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies	nan	RECRUITING
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects	nan	WITHDRAWN
A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)	nan	WITHDRAWN
Azoospermia Patients	nan	RECRUITING
Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ZFP91 binder may also engage these)

Protein	Name	Similarity
Q62511	—	1.000	Q62511 →
A4FV61	—	0.980	A4FV61 →
Q8K2W6	—	0.979	Q8K2W6 →
Q8CE64	—	0.978	Q8CE64 →
Q92667	—	0.978	Q92667 →
Q9WU42	—	0.977	Q9WU42 →
Q9BE73	—	0.976	Q9BE73 →
D4A7U2	—	0.976	D4A7U2 →
Q5U2T6	—	0.976	Q5U2T6 →
P39881	—	0.976	P39881 →
Q5R6F3	—	0.975	Q5R6F3 →
Q9QYE0	—	0.975	Q9QYE0 →
Q9Z2D6	—	0.975	Q9Z2D6 →
Q17R98	—	0.975	Q17R98 →
Q99NA2	—	0.975	Q99NA2 →
F7AQ22	—	0.974	F7AQ22 →
Q96ME7	—	0.974	Q96ME7 →
Q6NXK2	—	0.974	Q6NXK2 →
Q8CDC7	—	0.974	Q8CDC7 →
Q5XJV7	—	0.974	Q5XJV7 →
Q5TC79	—	0.973	Q5TC79 →
NCOR2	Nuclear receptor corepressor 2	0.973	landscape →
Q4V7B1	—	0.973	Q4V7B1 →
Q8WY91	—	0.973	Q8WY91 →
BRD8	Bromodomain-containing protein 8	0.973	landscape →
Q8BSV3	—	0.973	Q8BSV3 →
P97432	—	0.972	P97432 →
Q505G8	—	0.972	Q505G8 →
Q96C00	—	0.972	Q96C00 →
Q9NQV5	—	0.972	Q9NQV5 →